Stay updated with breaking news from Ybgj. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Yubo International Biotech Limited (OTCMKTS:YBGJ – Get Free Report) saw a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 100 shares, a drop of 90.9% from the March 31st total of 1,100 shares. Based on an average daily volume of 500 shares, the days-to-cover […] ....
Yubo International Biotech Limited (OTCMKTS:YBGJ – Get Free Report)’s share price dropped 39.2% during mid-day trading on Wednesday . The company traded as low as $0.21 and last traded at $0.21. Approximately 100 shares traded hands during trading, a decline of 98% from the average daily volume of 6,489 shares. The stock had previously closed […] ....
Yubo International Biotech (OTCMKTS:YBGJ – Get Rating) and CONMED (NASDAQ:CNMD – Get Rating) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations. Volatility and Risk Yubo International Biotech has a beta of […] ....
Yubo International Biotech (OTCMKTS:YBGJ – Get Rating) and CONMED (NASDAQ:CNMD – Get Rating) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk. Insider & Institutional Ownership 13.7% of Yubo International Biotech shares […] ....
Yubo International Biotech (OTCMKTS:YBGJ – Get Rating) and LivaNova (NASDAQ:LIVN – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Institutional & Insider Ownership 97.3% of LivaNova shares are held […] ....